Patients with IDH-mutant glioma frequently experience symptoms such as fatigue, seizures, headaches, cognitive impairments (primarily attentional), and mood changes, which can significantly affect their health-related quality of life (HRQoL). Disease progression and treatment-related toxicities are the two primary factors driving the decline in HRQoL in this population. These symptoms can be exacerbated by side effects from available therapeutic options, such as chemotherapy, radiation therapy, or targeted IDH inhibitors. In this context, it is crucial to consider the combined effects of these treatments on patient symptoms and HRQoL. Given that this population is young and otherwise healthy, with long-term survival exceeding 10 years after diagnosis, it is essential to consider not only on longevity but also on overall functioning and HRQoL when making treatment decisions. Assessing quality of life has therefore become a key parameter in phase III clinical trials and observational studies under real-world conditions.
The Resilience PRO digital medical device (DMD; CE-marked class IIa) enables remote monitoring of patients treated for cancer who are receiving systemic therapy. Resilience PRO has been positively evaluated by the French National Health Authority (HAS) and included on the LATM list under its brand name. Resilience PRO sends validated weekly questionnaires to patients (NCI PRO-CTCAE ePatient Reported Outcomes \[ePROs\]), inquiring about treatment- and disease-related symptomatic adverse events. The associated alert algorithm, equivalent to those used in the STAR and PRO-TECT studies, allows for the proactive management of severe or worsening symptoms by the healthcare professional receiving the alert. Additionally, Resilience PRO provides patients with personalized access to a mobile app that offers resources aimed at improving education, self-management, and patient engagement. These innovations lead to clinical benefits (improved quality of life, reduced morbidity, and increased overall survival), as well as organizational benefits (reduced emergency room visits and hospitalizations) and economic advantages.
Adults (over 18 years of age)
Written consent from the patient to participate in the clinical study
Diagnosed with grade 2-4 glioma with IDH1/2 mutation
Plan to initiate new systemic treatment for glioma (chemotherapy, targeted therapy, or other investigational antitumor systemic agent)
Severe language impairment
Cognitive deficit preventing the understanding of essential elements for questionnaires
Patient under guardianship or curatorship
Single group
Neurocognitive assessment
Behavioral* Memory: * RL-RI 16 test (the French version of the Free and Cued Recall Test) * Recall after 3 minutes of the Rey Complex Figure Test * Digits forward (verbal/visual) WAIS III * Working memory: * Letter - number sequencing * Digits backward (verbal/visual) WAIS III * Language: * Short-Boston Naming test , for which normative data are in course of validation * Token test * Visuo-spatial ability: \- Copy subtest of the Rey Complex Figure Test * Cognitive executive functions: * Stroop test * Semantic fluency test * Letter fluency test * Behavioural executive functions: * ISDC (Dysexecutive questionnaire)
Questionnaries QoL
Other interventionQuestionnaires QLQ-C30 and EQ-5D-5L filled on the Resilience app Questionnaires FACT-Br and QLQ BN20 filled on paper forms
Resilience Pro Application
DeviceRemote monitoring using Resilience Pro Application for QoL questionnaries
The primary objective of the study is to assess the quality of life using the QLQ-C30 questionnaire in IDH-mutant gliomas patients in real-world conditions treated with systemic treatment (IDH inhibitor, PCV, TMZ).
QOL scores will be followed every two weeks using the Resilience PRO tool. QOL global score deterioration will be defined as a deterioration with a minimal clinically important difference ≥ 10 points as compared to the baseline score (V1 - M0) . Baseline score evaluation will be performed before the initiation of systemic therapy. Proportion of patient with a QoL score deterioration will be reported at clinically relevant timepoints such as 6 and 12 months.
assess the following outcomes in IDH-mutant gliomas patients in real-world conditions treated with systemic treatment:
Quality of life subscales score evolution between inclusion visit to end of study using the QLQ-C30 questionnaire
QOL score deterioration ≥ 5 points using the QLQ-C30 questionnaire
Quality of life global score deterioration will be defined as a deterioration with a minimal clinically important difference ≥ 5 points as compared to the baseline score (V1 - M0)
Time to QOL score deterioration
Time to Quality-of-life global score deterioration (defined as a change from baseline ≥ 5 points)
Time to severe adverse events
Time from inclusion to severe adverse events
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
